Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema Results from the Pan-American Collaborative Retina Study Group at 6-Month Follow-up

Arevalo, J. Fernando; Fromow-Guerra, Jans; Quiroz-Mercado, Hugo; Sanchez, Juan G.; Wu, Lihteh; Maia, Mauricio; Berrocal, Maria H.; Solis-Vivanco, Adriana; Farah, Michel E

doi:https://doi.org/10.1016/j.ophtha.2006.12.028

Ítem

Solo Metadatos

Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema Results from the Pan-American Collaborative Retina Study Group at 6-Month Follow-up

https://repository.urosario.edu.co/handle/10336/26225
https://doi.org/10.1016/j.ophtha.2006.12.028

Autores

Arevalo, J. Fernando

Fromow-Guerra, Jans

Quiroz-Mercado, Hugo

Sanchez, Juan G.

Wu, Lihteh

Maia, Mauricio

Berrocal, Maria H.

Solis-Vivanco, Adriana

Farah, Michel E

Fecha

2007-04

Editor

Elsevier

Buscar en:

Métricas alternativas

Abstract

Purpose: To report the 6-month anatomic and best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (Avastin) in patients with diabetic macular edema (DME). Design: Interventional retrospective multicenter study at 6 centers from 6 countries of patients with DME. Participants: We reviewed the clinical records of 88 consecutive patients (110 eyes) with DME. Seventyeight eyes of 64 consecutive patients with a minimum follow-up of 6 months and mean age of 59.7 9.3 years were included in this analysis

Keywords

Angiogenesis Inhibitors , Antibodies , Monoclonal , Antibodies , Monoclonal , Humanized , Bevacizumab , Diabetic Retinopathy , Female , Fluorescein Angiography , Follow-Up Studies , Humans , Injections , Macular Edema , Male , Middle Aged , Ophthalmoscopy , Retrospective Studies , Tomography , Optical Coherence , Treatment Outcome , Vascular Endothelial Growth Factor A , Visual Acuity , Vitreous Body